Ask about this productRelated genes to: MAOB antibody
- Gene:
- MAOB NIH gene
- Name:
- monoamine oxidase B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: MAOB antibody
Related articles to: MAOB antibody
- Astrocytes support synaptic activity and associated circuit function, including those linked to sleep and memory, though how they coordinate these processes remains poorly defined. Here, we show that the transcription factor Nuclear Factor I-X (NFIX) is required to maintain astrocyte function in the thalamic reticular nucleus (TRN), as its deletion results in aberrant thalamocortical oscillations and impaired memory formation. We found that NFIX directly regulates the expression of monoamine oxidase B (MAOB) and the purinergic receptor, P2RX7. Mechanistically, knockdown of Maob or knockout of P2rx7 in TRN astrocytes results in decreased astrocytic release of the neurotransmitter GABA, reducing tonic inhibition of ventrobasal (VB) relay neurons and impairing memory formation. Altogether, our studies identify region-specific roles for astrocytic NFIX and its gene regulatory network in TRN astrocytes, while further revealing that astrocytes in the TRN couple regulation of thalamocortical circuit dynamics and memory formation through parallel GABA and purinergic signaling pathways. - Source: PubMed
Publication date: 2026/08/13
Murali SanjanaSilva-Pérez ManuelWoo JunsungPatel PriyankaKo YeunjungKwon WookbongSanchez KaitlynBorges da Silva HenriqueGronostajski RichardChin JeannieDeneen Benjamin - This study used an in vitro simulated digestion model combined with network pharmacology to investigate the bioaccessibility, dynamic changes in antioxidant capacity, and potential molecular mechanisms by which active components of sugarcane vinegar mitigate alcoholic liver disease (ALD). The results showed that the bioaccessibility of total phenols, total flavonoids, and reducing sugars in sugarcane vinegar exceeded 90% during gastric digestion. However, after combined gastrointestinal digestion, the bioaccessibility of total flavonoids was reduced significantly (39.39%). Among the phenilic phenolic monomers, ferulic acid had the highest gastric bioaccessibility index (419.10%), while luteolin exhibited the strongest stability throughout digestion process. The 2,2-Diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging and total reducing capacity gradually decreased, whereas the 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) reached its peak during gastrointestinal digestion. Correlation analysis showed that antioxidant capacity was closely correlated with phenolic compounds. Alcohol detoxification experiments revealed the ethanol retention rate of sugarcane vinegar during gastric digestion was significantly higher (14%) than undigested sample. Network pharmacology analysis identified caffeic, ferulic, protocatechuic, vanillic, and gentisic acid in sugarcane vinegar, with MAOB, PTGS1, and PTGS2 targets. These molecular docking findings reveal the strong binding affinity between polyphenols and their core targets. This research establishes a robust theoretical framework for harnessing sugarcane vinegar bioactive properties as a functional food strategy to mitigate alcoholic liver disease. - Source: PubMed
Publication date: 2026/08/06
Wu FeifeiZheng FengjinLin BoCheng HaoTan YuanYang YuxiaVerma Krishan KChen Ganlin - Based on previous work, a series of 6-benzyloxybenzo[c]thiophen-1(3H)-one derivatives endowed with HS-releasing properties were designed and synthesized. These compounds were tailored to act as selective MAO-B inhibitors with concurrent antioxidant, anti-neuroinflammatory, and neuroprotective activities, along with a favorable drug-like profile. Among them, compound 12d exhibited the most balanced pharmacological profile, functioning as a highly potent, reversible, and competitive MAO-B inhibitor (IC = 0.35 nM, SI = 6342.8) with moderate free-radical scavenging ability (0.59 Trolox equivalent). In vitro cellular models further confirmed its pronounced neuroprotective and anti-inflammatory efficacies. Pharmacokinetic profiling revealed that 12d possesses a suitable half-life and central nervous system penetrability, along with markedly improved water solubility. Importantly, in vivo studies demonstrated that oral administration of 12d alleviated motor deficits in a subacute MPTP-induced PD mouse model, accompanied by restored dopamine and HS levels, reduced malondialdehyde content, and significantly preserved tyrosine hydroxylase (TH)-positive neurons in the brain. Collectively, these findings validate 12d as an innovative, multi-target candidate with considerable potential for the treatment of Parkinson's disease. - Source: PubMed
Publication date: 2026/08/08
Cong ShiqinTang KeLi JingjingGu RuifangChen ChenLuo JingningWen JingXu YidanKe YafangLiu XiuxiuHuang YuchuanDeng Yong - Alzheimer disease (AD) and Parkinson disease (PD) are multifactorial neurodegenerative disorders for which there is currently no therapy that prevents or slows their progress. Some drugs used to treat AD are inhibitors of acetylcholinesterase (AChE) and antagonists of N-methyl-D-aspartate receptor (NMDAr), while inhibitors of catechol-O-methyltransferase (COMT) and monoamine oxidase B (MAO-B) are used for PD. Tacrine was the first FDA (Food and Drug Administration) approved drug against AD. Although later withdrawn due to hepatotoxicity, it remains a pivotal scaffold for drug development. Herein, 1295 tacrine derivatives, meant to enhance therapeutic efficacy and safety of the parent compound, were designed through the CADMA-Chem protocol. The chemical space was screened using selection scores based on ADME properties, toxicity, and synthetic accessibility. Two derivatives with the best drug-like behavior were chosen for further investigation. Acid-base constants and reactivity descriptors were estimated for them. Our findings show that these derivatives are promising inhibitors of AChE, COMT, NMDAr, and MAO-B. Therefore, according to in silico predictions they are expected to be beneficial for AD and PD. One of the compounds investigated here is the first reported tacrine-derived compound with potential as COMT inhibitor. - Source: PubMed
Dzib EugeniaHernández-Ayala Luis FelipeSilva-Aguirre SilvanaGalano Annia - Considering the shared physiological mechanisms between Alzheimer's disease (AD) and Parkinson's disease (PD), it is plausible that certain compounds may exert therapeutic effects on both neurological disorders. This study aimed to employ in silico techniques to investigate the pharmacological mechanisms of huperzine A (HA) as an alternative treatment for PD and AD. - Source: PubMed
Publication date: 2026/07/28
Ramirez-Contreras Luis AntonioCamargo-Hernández GabrielaSanchez-Enriquez SergioSilva-Jara Jorge ManuelHernández Estrada SalvadorHernández Villaseñor Luis AlfonsoAnaya Esparza Luis Miguel